Welcome to LookChem.com Sign In|Join Free
  • or
1H-Benzimidazole-6-sulfonyl chloride, 1-[(2,4-dichlorophenyl)methyl]-2-methyl- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

193012-70-3

Post Buying Request

193012-70-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

193012-70-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 193012-70-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,3,0,1 and 2 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 193012-70:
(8*1)+(7*9)+(6*3)+(5*0)+(4*1)+(3*2)+(2*7)+(1*0)=113
113 % 10 = 3
So 193012-70-3 is a valid CAS Registry Number.

193012-70-3Upstream product

193012-70-3Relevant academic research and scientific papers

Method of inhibiting neoplastic cells with benzimidazole derivatives

-

, (2008/06/13)

A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to benzimidazole derivatives.

Benzimidazole compounds

-

Page column 150, (2010/02/05)

A benzimidazole compound represented by the formula (I): wherein R3is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 193012-70-3